1058 related articles for article (PubMed ID: 25677428)
1. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.
Perros F; Ranchoux B; Izikki M; Bentebbal S; Happé C; Antigny F; Jourdon P; Dorfmüller P; Lecerf F; Fadel E; Simonneau G; Humbert M; Bogaard HJ; Eddahibi S
J Am Coll Cardiol; 2015 Feb; 65(7):668-80. PubMed ID: 25677428
[TBL] [Abstract][Full Text] [Related]
2. Improvement of left ventricular diastolic function induced by β-blockade: a comparison between nebivolol and metoprolol.
Fang Y; Nicol L; Harouki N; Monteil C; Wecker D; Debunne M; Bauer F; Lallemand F; Richard V; Thuillez C; Mulder P
J Mol Cell Cardiol; 2011 Aug; 51(2):168-76. PubMed ID: 21640121
[TBL] [Abstract][Full Text] [Related]
3. Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol.
Wolf SC; Sauter G; Preyer M; Poerner T; Kempf VA; Risler T; Brehm BR
Cell Physiol Biochem; 2007; 19(1-4):129-36. PubMed ID: 17310107
[TBL] [Abstract][Full Text] [Related]
4. The beta-adrenergic receptor in pulmonary arterial hypertension: a novel therapeutic target?
Rubin LJ
J Am Coll Cardiol; 2015 Feb; 65(7):681-3. PubMed ID: 25677429
[No Abstract] [Full Text] [Related]
5. [Pharmacological modulation of NO synthesis in patients with arterial hypertension and endothelial dysfunction].
Buval'tsev VI; Spasskaia MB; Nebieridze DV; Metel'skaia VA; Guseva OI
Klin Med (Mosk); 2003; 81(7):51-5. PubMed ID: 12934313
[TBL] [Abstract][Full Text] [Related]
6. Nebivolol attenuates prooxidant and profibrotic mechanisms involving TGF-β and MMPs, and decreases vascular remodeling in renovascular hypertension.
Ceron CS; Rizzi E; Guimarães DA; Martins-Oliveira A; Gerlach RF; Tanus-Santos JE
Free Radic Biol Med; 2013 Dec; 65():47-56. PubMed ID: 23806385
[TBL] [Abstract][Full Text] [Related]
7. Nebivolol prevents desensitization of β-adrenoceptor signaling and induction of cardiac hypertrophy in response to isoprenaline beyond β1-adrenoceptor blockage.
Ozakca I; Arioglu-Inan E; Esfahani H; Altan VM; Balligand JL; Kayki-Mutlu G; Ozcelikay AT
Am J Physiol Heart Circ Physiol; 2013 May; 304(9):H1267-76. PubMed ID: 23457011
[TBL] [Abstract][Full Text] [Related]
8. β1-Adrenergic blockers exert antioxidant effects, reduce matrix metalloproteinase activity, and improve renovascular hypertension-induced cardiac hypertrophy.
Rizzi E; Guimaraes DA; Ceron CS; Prado CM; Pinheiro LC; Martins-Oliveira A; Gerlach RF; Tanus-Santos JE
Free Radic Biol Med; 2014 Aug; 73():308-17. PubMed ID: 24933619
[TBL] [Abstract][Full Text] [Related]
9. Nebivolol: an endothelium-friendly selective β1-adrenoceptor blocker.
Gao Y; Vanhoutte PM
J Cardiovasc Pharmacol; 2012 Jan; 59(1):16-21. PubMed ID: 21283024
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib alleviates experimental pulmonary arterial hypertension.
Kim SY; Lee JH; Huh JW; Kim HJ; Park MK; Ro JY; Oh YM; Lee SD; Lee YS
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):698-708. PubMed ID: 22842494
[TBL] [Abstract][Full Text] [Related]
11. Major differences in gene expression in human coronary smooth muscle cells after nebivolol or metoprolol treatment.
Wolf SC; Sauter G; Jobst J; Kempf VA; Risler T; Brehm BR
Int J Cardiol; 2008 Mar; 125(1):4-10. PubMed ID: 17467819
[TBL] [Abstract][Full Text] [Related]
12. Eicosapentaenoic acid ameliorates pulmonary hypertension via inhibition of tyrosine kinase Fyn.
Kurahara LH; Hiraishi K; Yamamura A; Zhang Y; Abe K; Yahiro E; Aoki M; Koga K; Yokomise H; Go T; Ishikawa K; Bo Z; Kishi H; Kobayashi S; Aoki-Shoi N; Toru S; Inoue R; Hirano K
J Mol Cell Cardiol; 2020 Nov; 148():50-62. PubMed ID: 32889002
[TBL] [Abstract][Full Text] [Related]
13. Nebivolol, but not metoprolol, improves endothelial function of the corpus cavernosum in apolipoprotein e-knockout mice.
Baumhäkel M; Schlimmer N; Büyükafsar K; Arikan O; Böhm M
J Pharmacol Exp Ther; 2008 Jun; 325(3):818-23. PubMed ID: 18364472
[TBL] [Abstract][Full Text] [Related]
14. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells.
Brehm BR; Wolf SC; Bertsch D; Klaussner M; Wesselborg S; Schüler S; Schulze-Osthoff K
Cardiovasc Res; 2001 Feb; 49(2):430-9. PubMed ID: 11164853
[TBL] [Abstract][Full Text] [Related]
15. NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension.
Dumas SJ; Bru-Mercier G; Courboulin A; Quatredeniers M; Rücker-Martin C; Antigny F; Nakhleh MK; Ranchoux B; Gouadon E; Vinhas MC; Vocelle M; Raymond N; Dorfmüller P; Fadel E; Perros F; Humbert M; Cohen-Kaminsky S
Circulation; 2018 May; 137(22):2371-2389. PubMed ID: 29444988
[TBL] [Abstract][Full Text] [Related]
16. Nebivolol: impact on cardiac and endothelial function and clinical utility.
Toblli JE; DiGennaro F; Giani JF; Dominici FP
Vasc Health Risk Manag; 2012; 8():151-60. PubMed ID: 22454559
[TBL] [Abstract][Full Text] [Related]
17. Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension.
Ricard N; Tu L; Le Hiress M; Huertas A; Phan C; Thuillet R; Sattler C; Fadel E; Seferian A; Montani D; Dorfmüller P; Humbert M; Guignabert C
Circulation; 2014 Apr; 129(15):1586-97. PubMed ID: 24481949
[TBL] [Abstract][Full Text] [Related]
18. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats.
Oelze M; Daiber A; Brandes RP; Hortmann M; Wenzel P; Hink U; Schulz E; Mollnau H; von Sandersleben A; Kleschyov AL; Mülsch A; Li H; Förstermann U; Münzel T
Hypertension; 2006 Oct; 48(4):677-84. PubMed ID: 16940222
[TBL] [Abstract][Full Text] [Related]
19. Hydrogen ameliorates pulmonary hypertension in rats by anti-inflammatory and antioxidant effects.
Kishimoto Y; Kato T; Ito M; Azuma Y; Fukasawa Y; Ohno K; Kojima S
J Thorac Cardiovasc Surg; 2015 Sep; 150(3):645-54.e3. PubMed ID: 26095621
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of baicalin on monocrotaline-induced pulmonary arterial hypertension by inhibiting inflammatory response.
Luan Y; Chao S; Ju ZY; Wang J; Xue X; Qi TG; Cheng GH; Kong F
Int Immunopharmacol; 2015 May; 26(1):188-93. PubMed ID: 25601497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
